230 related articles for article (PubMed ID: 11269740)
1. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
Dowlati A; Levitan N; Gordon NH; Hoppel CL; Gosky DM; Remick SC; Ingalls ST; Berger SJ; Berger NA
Cancer Chemother Pharmacol; 2001; 47(2):141-8. PubMed ID: 11269740
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide.
Miller AA; Niell HB
Lung Cancer; 2001; 33(2-3):241-8. PubMed ID: 11551419
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients.
Huisman C; Postmus PE; Giaccone G; Smit EF
Ann Oncol; 2001 Nov; 12(11):1567-73. PubMed ID: 11822756
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
5. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
6. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
Crump M; Lipton J; Hedley D; Sutton D; Shepherd F; Minden M; Stewart K; Beare S; Eisenhauer E
Leukemia; 1999 Mar; 13(3):343-7. PubMed ID: 10086724
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
Herben VM; ten Bokkel Huinink WW; Dubbelman AC; Mandjes IA; Groot Y; van Gortel-van Zomeren DM; Beijnen JH
Br J Cancer; 1997; 76(11):1500-8. PubMed ID: 9400949
[TBL] [Abstract][Full Text] [Related]
10. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
[TBL] [Abstract][Full Text] [Related]
11. A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.
Cooper BW; Donaher E; Lazarus HM; Green SB; Gosky DM; Rosenthal NS; Berger SJ; Li X; Ingalls ST; Hoppel CL; Gerson SL
Leuk Res; 2003 Jan; 27(1):35-44. PubMed ID: 12479850
[TBL] [Abstract][Full Text] [Related]
12. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
[TBL] [Abstract][Full Text] [Related]
13. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
[TBL] [Abstract][Full Text] [Related]
14. Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Mainwaring MG; Rimsza LM; Chen SF; Gomez SP; Weeks FW; Reddy V; Lynch J; May WS; Kahn S; Moreb J; Leather H; Braylan R; Rowe TC; Fieniewicz KJ; Wingard JR
Leuk Lymphoma; 2002 May; 43(5):989-99. PubMed ID: 12148910
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
16. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
Rose PG; Markman M; Bell JG; Fusco NL
Gynecol Oncol; 2006 Aug; 102(2):236-9. PubMed ID: 16412499
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
Kancherla RR; Nair JS; Ahmed T; Durrani H; Seiter K; Mannancheril A; Tse-Dinh YC
Cancer; 2001 Feb; 91(3):463-71. PubMed ID: 11169927
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer.
Kindler HL; Kris MG; Smith IE; Miller VA; Grant SC; Krebs JB; Ross GA; Slevin ML
Am J Clin Oncol; 1998 Oct; 21(5):438-41. PubMed ID: 9781595
[TBL] [Abstract][Full Text] [Related]
19. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
[TBL] [Abstract][Full Text] [Related]
20. New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
Huang CH; Treat J
Oncology; 2001; 61 Suppl 1():14-24. PubMed ID: 11598410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
